Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7a pseudogene 69 (RPL7AP69) is a non-functional genomic DNA sequence that originated from the reverse transcription and genomic integration of the mRNA of the RPL7A gene, which encodes a protein component of the large 60S ribosomal subunit. Unlike the parent protein-coding gene RPL7A—which is responsible for protein synthesis as part of the ribosome—RPL7AP69 does not code for a functional protein[1][4]. Pseudogenes like RPL7AP69 can occasionally have regulatory or post-transcriptional roles, but there is no current evidence for such functionality for this pseudogene. It is not considered a therapeutic target, receptor, enzyme, transporter, or druggable entity, and has no established clinical or biomarker roles[8][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7a pseudogene 69 (RPL7AP69).